Search Results
Jan 05, 2026, 13:04 ET W. L. GORE & ASSOCIATES ADQUIERE CONFORMAL MEDICAL, AMPLIANDO SU PRESENCIA EN TRATAMIENTOS ENDOVASCULARES
pacientes con fibrilación auricular no valvular (AFib) que busca reducir el riesgo de formación de coágulos sanguíneos en la LAA que causan accidentes cerebrovasculares y eliminar la necesidad de terapia anticoagulante oral diaria a largo plazo. Se proyecta que la AFib alcanzará más de 12 millones de casos en
More news about: W. L. GORE & ASSOCIATES
Jan 05, 2026, 09:37 ET W. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL, EXPANDING ITS PRESENCE IN ENDOVASCULAR TREATMENTS
use.LAAO is a one-time procedure for patients with non-valvular atrial fibrillation (AFib) that aims to reduce the risk of stroke-causing blood clots forming in the LAA and eliminate the need for long-term daily oral anticoagulant therapy. AFib is projected to reach more than 12 million cases in
More news about: W. L. GORE & ASSOCIATES
Jan 05, 2026, 09:18 ET W. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL, EXPANDING ITS PRESENCE IN ENDOVASCULAR TREATMENTS
use.LAAO is a one-time procedure for patients with non-valvular atrial fibrillation (AFib) that aims to reduce the risk of stroke-causing blood clots forming in the LAA and eliminate the need for long-term daily oral anticoagulant therapy. AFib is projected to reach more than 12 million cases in
More news about: W. L. GORE & ASSOCIATES
Dec 22, 2025, 09:00 ET Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year. Approximately 12 million people in the United States over the age of 65 have AFib, a number expected
More news about: Abbott
Nov 25, 2025, 07:00 ET Impilo Expands Digital Health Offerings Through Partnership with Eko Health, Featuring the Eko CORE 500™ Digital Stethoscope
sounds, and access AI-supported insights, helping to elevate diagnostic confidence and streamline patient assessments.Disclaimer: AFib and murmur detection are supported by Eko AI and require an Eko+ membership. Eko+ membership provides access to Eko AI in the software in countries
More news about: Impilo
Nov 19, 2025, 10:20 ET Amy Rudolph, PhD, Joins Thryv Therapeutics' Board of Directors to Support Portfolio Progression into Heart Failure
SGK1 inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure (HF), and atrial fibrillation (AFib)—three serious cardiac conditions with urgent unmet medical needs. About Thryv TherapeuticsThryv
More news about: Thryv Therapeutics Inc.
Nov 18, 2025, 06:45 ET Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum
acceleration of revenue growth in the back half of the year and beyond, driven by several enterprise growth drivers, including our PFA franchise for Afib, Symplicity™ procedure for hypertension, Hugo™ robotic-assisted surgery system, and Altaviva™ therapy for urge urinary incontinence."
More news about: Medtronic plc
Nov 10, 2025, 08:00 ET Johnson & Johnson lança plataforma VARIPULSE™ no Brasil e avança no tratamento da fibrilação atrial
https://www.heart.org/en/health-topics/atrial-fibrillation/what-are-the-symptoms-of-atrial-fibrillation-afib-or-af xv Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM,
More news about: Johnson & Johnson MedTech
Oct 28, 2025, 17:34 ET OMRON Healthcare Wins Best in Class in the 2025 Digital Health Awards at HLTH
expectant moms throughout pregnancy." "Atrial fibrillation (AFib) is widely undiagnosed. The health risks of AFib increase for those with high blood pressure and women in menopause. With OMRON IntelliSense™ AFib detection, we are helping people act on this condition earlier than ever before,"
More news about: OMRON Healthcare
Oct 14, 2025, 10:03 ET Conformal Medical Announces First Patient Enrollment in the E.U. for CONFORM Pivotal Trial with The CLAAS® AcuFORM™ LAAO Device
patients with non-valvular atrial fibrillation (AFib). "The CLAAS AcuFORM system represents an important innovation in LAAO, with the potential to simplify procedures, expand access, and improve outcomes for patients with non-valvular AFib," said Dr. Garot. "We are excited to participate
More news about: Conformal Medical, Inc.
Oct 14, 2025, 10:03 ET Conformal Medical Announces First Patient Enrollment in the E.U. for CONFORM Pivotal Trial with The CLAAS® AcuFORM™ LAAO Device
patients with non-valvular atrial fibrillation (AFib). "The CLAAS AcuFORM system represents an important innovation in LAAO, with the potential to simplify procedures, expand access, and improve outcomes for patients with non-valvular AFib," said Dr. Garot. "We are excited to participate
More news about: Conformal Medical, Inc.
Oct 07, 2025, 08:36 ET HeartX Cardiovascular Accelerator Announces Seven Startup Companies Selected for the 2025 Program
non-invasive therapy for atrial fibrillation (AFib). Its wearable device delivers proprietary neuromodulation therapy along with artificial intelligence (AI)-powered advanced cardiac rhythm monitoring. This closed-loop therapy approach enables personalized AFib management at home. Early clinical evidence
More news about: HeartX
Oct 02, 2025, 21:13 ET OMRON Healthcare übertrifft die Marke von 400 Millionen verkauften Blutdruckmessgeräten
um die präventive Gesundheitsversorgung zu unterstützen, einschließlich der Bemühungen, potenziell lebensbedrohliche Erkrankungen wie Vorhofflimmern (AFib) frühzeitig zu erkennen. Mit Beginn eines neuen Kapitels tragen die branchenführenden Geräte und digitalen Gesundheitsplattformen
More news about: OMRON HEALTHCARE Co., Ltd.
Oct 02, 2025, 01:46 ET OMRON Healthcare supera los 400 millones de tensiómetros vendidos
y compartir información con la familia y en las consultas con el médico. - Detección basada en IA: la tecnología Intellisense AFib (TM), única y aprobada por la Administración de Alimentos y Medicamentos (FDA, por sus siglas en inglés), permite la detección precoz de la fibrilación
More news about: OMRON HEALTHCARE Co., Ltd.
Oct 01, 2025, 08:02 ET OMRON Healthcare ultrapassa 400 milhões de monitores de pressão arterial vendidos
apoiar os cuidados preventivos com a saúde, incluindo esforços para detectar precocemente condições potencialmente fatais, como a fibrilação atrial (AFib). À medida que um novo capítulo se inicia, os dispositivos líderes do setor e as plataformas de saúde digital da OMRON Healthcare
More news about: OMRON HEALTHCARE Co., Ltd.
Sep 30, 2025, 02:26 ET OMRON Healthcare dépasse les 400 millions de tensiomètres vendus
soins de santé préventifs, y compris les efforts visant à détecter les conditions potentiellement mortelles telles que la fibrillation auriculaire (AFib) à un stade précoce. Alors qu'un nouveau chapitre s'ouvre, les appareils de pointe et les plateformes de santé numérique d'OMRON
More news about: OMRON HEALTHCARE Co., Ltd.
Sep 29, 2025, 21:27 ET 歐姆龍健康醫療血壓計銷量突破4億台
—互聯數字健康監測：配備藍牙功能的設備能夠與OMRON connect (TM)應用程序無縫連接，支持數據趨勢可視化展示、家庭成員數據共享以及醫生遠程監控。 —人工智能(AI)驅動檢測：獨一無二、獲得FDA認證的Intellisense AFib (TM)技術，可以在常規監測中實現房顫的早期識別。 —集成式測量：Complete (TM)監測儀可以同步測量血壓與ECG數據，並通過OMRON connect (TM)應用程序無縫共享給醫生。 —遠程監測合作：歐姆龍旗下Digital
More news about: Omron Healthcare Co., Ltd.
Sep 29, 2025, 04:00 ET OMRON Healthcare Exceeds 400M Blood Pressure Monitors Sold
pressure management to support preventive healthcare, including efforts to detect potentially life-threatening conditions such as atrial fibrillation (AFib) at an early stage. As a new chapter begins, OMRON Healthcare's industry-leading devices and digital health platforms continue
More news about: OMRON HEALTHCARE Co., Ltd.
Sep 29, 2025, 04:00 ET OMRON Healthcare Exceeds 400M Blood Pressure Monitors Sold
pressure management to support preventive healthcare, including efforts to detect potentially life-threatening conditions such as atrial fibrillation (AFib) at an early stage. As a new chapter begins, OMRON Healthcare's industry-leading devices and digital health platforms
More news about: OMRON HEALTHCARE Co., Ltd.
Sep 11, 2025, 09:00 ET AI-Enabled Eko Health Stethoscope TRICORDER Trial Marks Historic Leap in Early Heart Disease Detection
period compared to the standard of care: Heart failure: 2.3x more likely to be detectedAtrial fibrillation (AFib): 3.5x more likely to be detectedValvular heart disease: 1.9x more likely to be detectedThese findings,
More news about: Eko Health